{"id":9062,"date":"2022-06-23T12:41:00","date_gmt":"2022-06-23T10:41:00","guid":{"rendered":"https:\/\/czecrin.cz\/project\/kh-half\/"},"modified":"2026-01-06T09:56:23","modified_gmt":"2026-01-06T08:56:23","slug":"kh-half","status":"publish","type":"project","link":"https:\/\/czecrin.cz\/en\/project\/kh-half\/","title":{"rendered":"CT HALF"},"content":{"rendered":"\n

CLINICAL TRIAL HALF<\/h3>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

Prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor discontinuation after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission<\/em><\/p>\n\n\n\n

The HALF clinical trial is designed as a prospective, multicentre, non-randomised, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukaemia in deep remission. The HALF clinical trial could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves but also for the healthcare system. <\/p>\n\n\n\n

OVERVIEW OF RECRUITMENT<\/h6>\n\n\n\n

The planned number of subjects for the HALF study was 150 patients. This number was reached in January 2022. Recruitment was completed as of June 30, 2023 with a total of 221 patients enrolled. The infographic below shows the involvement of the collaborating sites in terms of number of subjects enrolled. <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Important links to the project<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
Access to REDCap database (for examiners)<\/a><\/strong><\/td>KH registration on ClinicalTrials.gov<\/a><\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n\n

Project documents<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
Approval of KH MEK FN Brno<\/strong><\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n\n

If you are interested in the full version of the ICF, or other KH documentation, please contact rychlickova@med.muni.cz<\/a><\/p>\n\n\n\n

<\/div>\n\n\n\n
Contact<\/h5>\n\n\n\n

National coordinator of the HALF study:
doc. MUDr. Daniela \u017d\u00e1\u010dkov\u00e1, Ph.D. | zackova.daniela@fnbrno.cz<\/a> | +420 532 232 838<\/a> <\/p>\n\n\n\n

<\/div>\n\n\n\n

Project managers:
PharmDr. Jitka Rychl\u00ed\u010dkov\u00e1, Ph.D., BCPS | rychlickova@med.muni.cz<\/a>
PharmDr. Ad\u00e9la B\u00e1rtov\u00e1 | adela.bartova@med.muni.cz<\/a> <\/p>\n\n\n\n

<\/div>\n\n\n\n